SOTIO's LRRC15-Targeting ADC SOT106 Receives FDA Orphan Drug Designation for Osteosarcoma Treatment
核心洞察
SOTIO Biotech (搜索) received FDA Orphan Drug Designation for SOT106, a next-generation antibody-drug conjugate targeting LRRC15 (搜索) for osteosarcoma (搜索) treatment.
SOT106 combines SOTIO's LRRC15 (搜索)-targeted antibody with Rigachem Bio (搜索)'s Conjuall ADC platform technology, showing strong anti-tumor activity in preclinical sarcoma (搜索) models.
The designation addresses a critical unmet need in osteosarcoma (搜索), where therapeutic innovation has been limited for four decades and patients rely on intensive chemotherapy with significant toxicities.
SOTIO Biotech (搜索) announced that the U.S. Food and Drug Administration (搜索) has granted Orphan Drug Designation to SOT106 for the treatment of osteosarcoma (搜索), marking a significant milestone for this next-generation antibody-drug conjugate targeting leucine-rich repeat-containing 15 (LRRC15 (搜索)). The designation reinforces the therapeutic potential of SOT106 as a targeted therapy for a patient population with high unmet medical need.
Novel ADC Platform Addresses Sarcoma Treatment Gap
SOT106 represents a collaboration between SOTIO Biotech (搜索) and Rigachem Bio (搜索), combining SOTIO's LRRC15 (搜索)-targeted antibody with Rigachem Bio's ADC platform technology called Conjuall. LRRC15 serves as a clinically validated target that is broadly expressed across sarcoma (搜索) subtypes and in tumor-associated stroma, while maintaining low expression levels in normal tissue.
Preclinical studies have demonstrated strong anti-tumor activity in both soft tissue and osteosarcoma (搜索) models, with favorable tolerability profiles supporting a high therapeutic index. The program is designed to deliver an early and actionable clinical signal, with expansion potential across multiple solid tumors (搜索) beyond sarcoma (搜索).
Addressing Decades of Limited Innovation
Osteosarcoma (搜索) represents the most common bone cancer in children and adolescents, yet therapeutic options have remained largely unchanged for four decades. According to SOTIO CEO Radek Spisek, "Osteosarcoma is a devastating disease that has seen little therapeutic innovation over the past four decades. Treatment continues to rely on intensive chemotherapy regimens associated with significant toxicities and limited long-term benefit."
The current treatment landscape for sarcomas relies primarily on a combination of surgery, radiation, and chemotherapy. However, outcomes remain poor for patients with aggressive, recurrent, or metastatic disease. The rarity and biological heterogeneity of sarcomas, which comprise more than 70 distinct subtypes, have made therapeutic innovation particularly challenging, including the development of targeted approaches such as ADCs.
Clinical Development Timeline and Regulatory Benefits
SOTIO expects to initiate a first-in-human clinical trial of SOT106 in the second half of 2026. The Orphan Drug Designation provides several development incentives, including the potential for seven years of market exclusivity upon approval, waivers of certain regulatory fees, and enhanced interaction with FDA guidance throughout the development process.
The designation specifically addresses the urgent medical need in osteosarcoma (搜索), where a significant number of patients require amputation of the affected limb and face limited long-term treatment benefits from current therapeutic approaches.
Broader Pipeline Development
SOT106 is part of SOTIO's broader ADC pipeline, which includes multiple mono- and bispecific solid tumor programs at various stages of preclinical development. The company is also advancing SOT109 for colorectal cancer (搜索) treatment and SOT201, a next-generation PD-1 (搜索)-targeting immunocytokine currently being evaluated in the Phase 1 VICTORIA-01 study for patients with solid tumors (搜索).